Organization | Syros Pharmaceuticals

Syros Pharmaceuticals Report issue

For profit Phase 1 Phase 2 Phase 3

Founded: Watertown MA United States (2012)

Organization Overview

First Clinical Trial

2016

NCT02807558

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Syros Pharmaceuticals

Active Ingredients

Drugs in Phase 3 Trials (2)

azacitidine (vidaza) (3 trials)

venetoclax (venclexta) (2 trials)

Drugs in Phase 2 Trials (11)

Key: Syros Pharmaceuticals (1) Acquired (10)

capecitabine (xeloda) (1 trial)

fluorouracil (efudex) (1 trial)

gemcitabine (gemzar) (1 trial)

methoxsalen (3 trials)

metyrosine (demser) (1 trial)

phenytoin (mesantoin) (3 trials)

sirolimus (rapamune) (3 trials)

sm-88 (2 trials)

tamibarotene (1 trial)

tyrosine isomers (1 trial)

Drugs in Phase 1 Trials (3)

arsenic trioxide (trisenox) (1 trial)

sy-1365 (1 trial)

sy-5609 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 1)

Preleukemia (Phase 2)

Syndrome (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 11
# of Trial APIs: 16